Aug. 13 at 4:04 PM
$MREO Keep on accumulating. 180 days prolongation will come. Will there be an reverse split? Most probably if other things are not sufficient to boost share price over 1 $. There are multiple inflection points within next 4 months, and there is no financial pressure for dilution. Financed until end of 2027 with received nonrefundable option fee, with Sentynl option excercise (up to 40 mio in funding) cash runaway most probably until YE 2029. Clarity on registrational path forward for Setrusumab. Phase 2 results by ReproNovo, Phase 2 start by ashibio. No own trials, very capital efficient business model while retaining European rights.
